Background: Major depressive disorder (MDD) is a severe, heritable
Introduction
Major depressive disorder (MDD) is a heritable and disabling psychiatric condition that has recently become the leading cause of disability worldwide (1) . Depression is associated with a number of age-related co-morbid physical conditions, including atherosclerosis, heart disease, hypertension and stroke (2). Further, MDD is associated with reduced life expectancy (3) . Faster biological ageing in MDD has been suggested as one possible mechanism for these associations (2, 4).
Several lines of convergent evidence support the premise of accelerated biological ageing in MDD. Firstly, genetic evidence demonstrates a significant overlap between molecular pathways implicated in depression and normal ageing (2, [4] [5] [6] . In some studies, particularly in the domains of memory and psychomotor speed, MDD and ageing are also both associated with reduced cognitive function as well as having overlapping structural and functional brain changes (5) . Telomere shortening, a measure associated with reduced lifespan and hence proposed as an objective measure of ageing, is also found in some studies of individuals with MDD (7, 8) .
DNA methylation changes are strongly associated with the ageing process and may give rise to downstream changes in gene expression and function (9) . More recently, studies addressing the dynamic nature of DNA methylation with age have identified various sites within the genome where changes preferentially occur (9) . DNA methylation levels at particular sites can be used to derive a score that is highly correlated with chronological age (10) (11) (12) . These 'epigenetic clocks' have also been shown to predict all-cause mortality and lifespan (13) (14) (15) ; those with faster running clocks relative to
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We primarily sought to determine if MDD status was associated with acceleration of biological ageing. We employed two commonly used measures of DNA methylation age (DNAm age): the Hannum and Horvath clocks (10) (11) (12) . We hypothesised that MDD would be associated with a higher DNAm age relative to chronological age, otherwise known as epigenetic age acceleration (EAA). We sought to test these predictions in a large populationbased cohort study, the Generation Scotland: Scottish Family Health Study sample (GH:SFHS) (16, 17) .
Methods and Materials

Study Participants Generation Scotland: the Scottish Family Health Study (GS:SFHS)
GS:SFHS is a family and population-based cohort study with participants recruited at random through general medical practices across Scotland. All participants were asked to refer at least one relative to the study, but neither recruitment nor referral of a relative was dependent on the diagnostic status of any particular condition or health outcome. Initial data collection took place between 2006 and 2011. The complete study protocol is described in detail elsewhere (16) (17) (18) . Brief details of assessments relevant to the current study are summarised below. Ethical approval was provided by NHS Tayside
Research Ethics Committee (05/S1401/89) and written consent for the use of data was obtained from all participants.
The full GS:SFHS cohort consisted of 23,690 individuals (>18 years of age at recruitment). The present study includes 5,052 individuals on whom DNA methylation data was acquired at baseline and subsequently analysed as part of a follow-up study of GS:SFHS participants, 'Stratifying Depression And Resilience Longitudinally' (STRADL). Briefly, individuals were selected for DNA methylation profiling based on the availability of existing longitudinal data. Individuals who participated in the Aberdeen Children of the 1950s and
Walker birth cohort studies were preferentially selected (19) (20) (21) , followed by those who provided further face-to-face or questionnaire-based phenotyping of depression status.
Clinical assessment in GS:SFHS
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MDD was diagnosed using the structured clinical interview for the Diagnostic and Statistical Manual of Mental Disorders (SCID) (22) . A brief screening questionnaire was administered in which participants were asked "Have you ever seen anybody for emotional or psychiatric problems?" and "Was there ever a time when you, or someone else, thought you should see someone because of the way you were feeling or acting?". If they answered 'yes' to either of these questions, they were asked to complete the SCID (22) . If they answered 'no' to both questions, they were assigned control status. Those who completed the SCID but did not meet the criteria for MDD or other major psychiatric disorder were also defined as controls. Individuals who declined to complete the screening questionnaire or SCID were not included in further analysis. Individuals were also asked about smoking and drinking status.
Individuals were asked 'Have you ever smoked tobacco?', or 'Have you ever had an alcoholic drink?'. They were requested to respond according to: (i)
Yes, currently smoke/drink, (ii) Yes, but stopped within past 12 months, (iii)
Yes, but stopped more than 12 months ago, (iv) No, never smoked/drank.
BMI was calculated using height (cm) and weight (kg) measured by trained clinical staff. 
Derivation of the epigenetic clock
Statistical modelling
All analyses were conducted in ASReml-R (www.vsni.co.uk/software/asreml, version 3.0). Associations were examined between EAA as the dependent variable and MDD status as the independent variable, controlling for sex using mixed linear model association analysis. Since GS:SFHS is a family-based study, family structure was fitted as a random effect by creating an inverse relationship matrix using pedigree kinship information to control for relatedness (25) . These covariates (sex, relatedness), as well as measures of blood cell-type composition (including CD8T, CD4T, NK, B cells and granulocytes, estimated using minfi's 'estimateCellCounts' function) and processing batch, were included in the basic model (13, 14) .
Further covariates were also added to test sensitivity of the regression model to potential confounding lifestyle and health-related factors previously associated with DNAm (full models). These included self-reported smoking and alcohol intake/consumption (as described above). In addition, since there is a known relationship between obesity and accelerated epigenetic ageing (26) , and between obesity and MDD (27), we also explored the contribution of body mass index (BMI, as a proxy for obesity) to the relationship between EAA and depression status. relationship between EAA and MDD, as mediated through BMI, using the 'testMediation' function in R using the Sobel method on an unrelated sample of individuals (controls n=1,301, MDD cases n=463). In each case EAA was entered as the independent variable, MDD status was entered as the dependent variable, and BMI was entered as the mediating variable.
Covariates included were sex, cell counts and batch, along with smoking and drinking status. For completeness, we also tested for mediation effects of smoking and drinking status on the relationship between EAA and depression status, see supplementary materials.
For all analyses, all continuous measures were rescaled into zero mean and unitary standard deviation in order that effect sizes represent standardized scores.
Results
Demographics
Sample characteristics are presented in ), and less likely to be current drinkers (χ 2 = 56.645, p = 3.06x10 -12 ) than control individuals (see Table 1 ). Body mass index (BMI) was greater in MDD cases than controls (controlling for sex,
), see Table 1 .
MDD Status and Epigenetic Age Acceleration (EAA): Basic Models
Epigenetic age and epigenetic age acceleration measures are presented in Table 1 for both clock-based methods for MDD cases and controls. No group differences were found for EAA Hannum in any of the models (Table 2 ). The EAA Horvath however indicated significantly increased epigenetic age acceleration in depressed cases versus controls, see Figure 1 , 
MDD Status and Epigenetic Age Acceleration (EAA): Full Models
To determine whether observed increases in EAA Horvath 
MDD * age/sex interaction effects
The inclusion of the age*MDD and sex*MDD interaction terms as covariates are presented in Supplementary Table 1a . The addition of these covariates either singly or together in the same model did not alter the main pattern of results described above for effects of MDD status (increased EAA in MDD cases), with the exception of the full models incrementally including all covariates plus BMI where results fell to just below significant (β=0.0644, p=0.051). Notably, the MDD*age interaction term was itself significant in these full models (β=-0.0723 to β =-0.0952, p<=0.05), as reflected in the divergence of the groups at the younger age range of the cohort, depicted in Figure 2 .
MDD*sex interactions were not significant.
Genetic correlation analysis: EAA, MDD and BMI
Genetic correlation analysis indicated there was a significant shared genetic architecture between EAA Horvath and BMI (r G =0.20, p=0.031), and between MDD and BMI (r G =0.10, p=9.86x10 -6 , see Table 3 , Figure 3 ), but not between 
Discussion
To our knowledge this is the largest study to date (>5,000 individuals) of epigenetic ageing in depressed cases versus controls. As hypothesised, we demonstrate that MDD is associated with a significantly higher EAA Horvath , contributing to the increasing body of evidence indicating accelerated biological ageing as a core feature of the disorder. The analysis further indicated that the observed epigenetic age acceleration effects in MDD were not due to confounding effects related to processing batch or cell counts, and
were not attributable to smoking or drinking status. This difference between cases and controls was small (equating to 0.20 years), which may in part relate to the extensive heterogeneity associated with MDD (33) . In contrast to our expectation that differences between MDD cases and controls would increase with age, we found larger differences in EAA towards the younger end of the cohort's age range (see Figure 2 ).
Numerous lines of evidence have previously led to suggestions of accelerated ageing effects in MDD. These include observations that depressed individuals demonstrate an increased risk of ageing-related diseases and reduced life expectancy (3), overlapping biological pathways involved in both MDD and biological ageing (5), and evidence of excessive cellular ageing (2, 4, 34). Ageing and ageing-related diseases are also notably associated with changes in DNA methylation, leading to the development of DNA methylation-based predictors of biological ageing (10) (11) (12) . It was previously unknown however, whether accelerated ageing effects at the level of methylation using such predictors would be seen in MDD, and how these may be mediated by other factors, for example BMI. There are known robust reciprocal links between obesity and depression (26) , and the role of increased BMI and shortened lifespan has also been extensively studied (35) .
More recently, studies have also reported that increases in BMI are associated with accelerated epigenetic ageing, although mechanisms are currently unknown, as are the links with comorbid diseases such as MDD (26) .
The current results support the idea that there is increased epigenetic age acceleration in depressed cases versus controls. We found evidence that these relationships were partially mediated by higher BMI (~13%), but not with smoking or drinking status. Future research probing the potential contributions of environmental and lifestyle influences on psychological well-being in the general population could highlight the importance of risk-related and protective factors of wide applicability.
Notably our findings between the two different DNAm age predictors differed in their sensitivity with regards the categorical depression diagnosis. It is notable however that there are differences between these two DNAm age methods that may contribute to these inconsistencies. The Hannum predictor is derived from whole blood DNA from a single cohort of individuals using 71
CpGs. The Horvath model was however derived from multiple tissue types using data from multiple independent studies and uses 353 CpGs. Further, each method involves almost entirely non-overlapping CpG sites. Although both methods perform similarly in their prediction of mortality (14, 36) , previous studies have also reported differences in their associations between other traits of interest, for example exposure to environmental particulate matter (37) , with neural integrity in post-traumatic stress disorder (36) , and with longevity (38). These studies, together with the current findings, therefore suggest that the two DNAm age biomarkers of biological ageing may reflect subtly different aspects of the ageing process.
The major strength of our study is the large sample size, with DNA methylation data available on more than 5,000 individuals, plus the availability of detailed phenotyping in our cohort. As sample sizes for GWAS of EAA increase, future work could include genetic analyses to inform causation models, such as Mendelian Randomisation. The lack of access to brain tissue is a frequently cited limitation of blood-based DNA methylation studies. Whilst we are unable to make strong inferences specifically about effects on the brain, other studies have indicated its suitability as a relevant for biomarker for such research purposes (11, 39) . Secondly, this study is cross-sectional in nature therefore it is not possible to infer causal directionality between factors.
Lastly, although we corrected for several confounders that might influence DNA methylation, such as sex, age*MDD, sex*MDD, smoking, drinking, and BMI, we cannot exclude the possibility that other factors not captured by our methods may have confounded the observed relationships.
In conclusion, our results indicate a significant increase in epigenetic 
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